The clinical management of solid malignancies remains constrained by the suboptimal therapeutic index of conventional chemotherapeutic agents, which arises from non-selective biodistribution, rapid systemic clearance, and the development of multidrug resistance. Pharmaceutical nanotechnology has engendered transformative platforms for addressing these limitations through the rational design of nanocarriers capable of tumor-selective drug deposition. This review provides a technical examination of two prominent nanocarrier classes—nanostructured lipid carriers (NLCs) and polymeric nanoparticles—with emphasis on their engineering principles and tumor microenvironment (TME)-responsive release mechanisms. NLCs, characterized by their imperfect crystalline matrix comprising blended solid and liquid lipids, offer enhanced drug loading capacity, prolonged stability, and compatibility with stimuli-responsive lipid excipients. Polymeric nanoparticles fabricated from biodegradable polymers such as poly (lactic-co-glycolic acid) (PLGA), chitosan, and polyethylene glycol (PEG) derivatives enable precise control over release kinetics and surface functionalization for active targeting. The pathophysiological features of the TME—including acidic pH, redox imbalance, enzymatic overexpression, and hypoxic gradients—serve as endogenous triggers for site-specific drug liberation through mechanisms including acid-labile bond cleavage, redox-sensitive linker degradation, and enzyme-activated shedding of protective coatings. Multi-stimuli responsive platforms integrating dual sensing capabilities are advancing toward spatiotemporally controlled delivery. A comparative evaluation of NLCs and polymeric nanoparticles reveals distinct advantages in drug loading, stability, and translational potential. While challenges in manufacturing scalability and regulatory approval persist, these nanotechnology-enabled strategies hold substantial promise for improving oncological outcomes through precision delivery.